Navigation Links
ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
Date:5/19/2011

EXTON, Pa., May 19, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

The objectives of this randomized, double-blind, placebo-controlled, dose ranging study are to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days in adults previously treated for CDI; characterize the frequency and duration of stool colonization with VP 20621 strain of C. difficile; evaluate the efficacy of VP 20621 for prevention of recurrence of CDI; and select a dose regimen of VP 20621 to be used in future studies.  Eligible subjects will have been diagnosed with CDI and treated with metronidazole or oral vancomycin.  Subjects will be randomized into four different therapy groups, with study drug administered once daily after completion of CDI antibiotic treatment and continuing for up to 14 days.  Each subject will be followed for a total of 6 months.  The study will enroll at least 240 subjects, and will be conducted in North America and Europe.  

"Recurrence of CDI represents a therapeutic challenge with substantial associated morbidity, mortality and compromised quality of life, often requiring prolonged and repeated treatment courses," commented Colin Broom, M.D., ViroPharma's chief scientific officer.  "There are no immediate solutions on the horizon for prevention of recurrent CDI following antibiotic treatment.  However, based on the Phase 1 data with VP 20621, we are encouraged that this novel approach may one day fill this unmet clinical need."

About VP 20621

Antibiotics including those used to treat acute C. difficile infection (CDI) dis
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
(Date:5/4/2015)... YORK , May 4, 2015  FireflySci Inc., the newest member of the cuvette ... after launch, they have turned the cuvette industry on its head by offering scientists amazing support ... http://photos.prnewswire.com/prnh/20150501/213243LOGO Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... 4, 2015 The Pharmacy Workforce Center recently ... that pharmacy has shifted toward a female-dominated profession. With ... managers, there is an incredible opportunity for women to ... decade. In a new blog post ... Insights , Eden Sulzer, director of the Women ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 2Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 3
(Date:5/4/2015)... McNeil & Company , a ... of coverage for its Emergency Services Insurance Program ... insurance and proactive risk management to the emergency services ... to providing our customers with unparalleled service and the ... We are excited to launch over 100 new enhancements ...
(Date:5/4/2015)... Orange, NJ (PRWEB) May 04, 2015 ... non-profit organization devoted exclusively to funding innovative lymphoma research ... of education programs, outreach initiatives and patient services – ... at the historic Mayfair Farms in West Orange, NJ ... raised nearly $500,000 for innovative research programs through LRF. ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 METTLER ... The Importance of Data Integrity in a GXP ... as guest presenter. This webinar will be presented ... GMT). , Data integrity is a critical component ... to regulatory agencies. However, in recent years an ...
(Date:5/4/2015)... WA (PRWEB) May 04, 2015 EyeCRO ... a collaboration to facilitate development of NM108, a first-in-class ... that lead to blindness, including Diabetic Retinopathy. The ... platform developed by EyeCRO, which can deliver drugs to ... topical eyedrop. , Under the terms of the ...
(Date:5/4/2015)... Greensboro, NC (PRWEB) May 04, 2015 ... excited to offer this unique program to other leadership ... create valuable ties between CCL and successful practitioners, expanding ... organizations around the globe,” said John R. Ryan, CCL ... consultancy joins the CCL Partner Network , it ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2
... loss to Argentina in a World Cup match in 1998 ... by 27 per cent. The fact that extreme stress and ... known to almost everyone.However, research carried out at the ... Argentina during the 1998 World Cup has provided further evidence ...
... The number of people suffering from spine problems is on ... disc and spinal canal stenosis. Herniated disc is more common ... spinal canal stenosis is common among// older people. Hitherto, both ... an incision of about 12cms to be made and the ...
... of the main concerns of teenagers heading back to school ... UT Southwestern Medical Center say that stress is one of ... stress produces increased secretion of the hormone androgen //which results ... likely to suffer from acne due to the hormonal changes ...
... new study involving twenty mothers and their full-term infants, ... regular sleep cycle. ,Dr. Sari Goldstein from Tel ... the perinatal // period helps infants coordinate their circadian ... clock that helps humans and other beings adjust to ...
... shown that smoking leads to damage of the protective reflexes ... from flowing back into the hroat and smoking causes damage ... chords if fluid enters the area, a condition known as ... by imaging the relex area before and after cigarettes. The ...
... study on both mice and humans are showing why some people ... that if you eat a fatty meal or snack - a ... cholesterol you absorb is strongly influenced by your genes. Experts know ... high fat diet is bad for you. But little has been ...
Cached Medicine News:
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... capability to quickly deliver up to 250 ... for powerful single-pulse ablation. This type of ... coldest and cleanest CO2 surgical laser available ... with the independent adjustment of pulse energy ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: